Format

Send to

Choose Destination
Elife. 2017 Apr 20;6. pii: e17137. doi: 10.7554/eLife.17137.

Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.

Author information

1
Disease Area Oncology, Novartis Institutes for BioMedical Research, Cambridge, United States.
2
Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
3
Genomics Institute of the Novartis Research Foundation, San Diego, United States.

Abstract

The efficacy of ALK inhibitors in patients with ALK-mutant neuroblastoma is limited, highlighting the need to improve their effectiveness in these patients. To this end, we sought to develop a combination strategy to enhance the antitumor activity of ALK inhibitor monotherapy in human neuroblastoma cell lines and xenograft models expressing activated ALK. Herein, we report that combined inhibition of ALK and MDM2 induced a complementary set of anti-proliferative and pro-apoptotic proteins. Consequently, this combination treatment synergistically inhibited proliferation of TP53 wild-type neuroblastoma cells harboring ALK amplification or mutations in vitro, and resulted in complete and durable responses in neuroblastoma xenografts derived from these cells. We further demonstrate that concurrent inhibition of MDM2 and ALK was able to overcome ceritinib resistance conferred by MYCN upregulation in vitro and in vivo. Together, combined inhibition of ALK and MDM2 may provide an effective treatment for TP53 wild-type neuroblastoma with ALK aberrations.

KEYWORDS:

ALK; MDM2; Neuroblastoma; TP53; cancer biology; human

PMID:
28425916
PMCID:
PMC5435462
DOI:
10.7554/eLife.17137
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for eLife Sciences Publications, Ltd Icon for PubMed Central
Loading ...
Support Center